ストックスクリーナーアプリを入手
5.35
10.54%
0.51
アフターアワーズ：
5.38
0.03
+0.56%
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
Orchestra BioMed’s Big Cash Infusion Sets Stage for High-Stakes Cardiology Trials - MSN
How currency fluctuations impact Orchestra BioMed Holdings Inc. stockDividend Hike & Low Drawdown Trading Strategies - newser.com
Will Orchestra BioMed Holdings Inc. stock outperform tech sector in 2025July 2025 Snapshot & Entry and Exit Point Strategies - newser.com
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease - MSN
Exit strategy if you’re trapped in Orchestra BioMed Holdings Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - newser.com
Is Orchestra BioMed Holdings Inc. stock supported by strong cash flowsWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Is Orchestra BioMed Ready For Landmark Year With Trial Enrollment And Cash Strength? - RTTNews
How sentiment analysis helps forecast Orchestra BioMed Holdings Inc.2025 Volatility Report & Expert Curated Trade Setups - newser.com
Orchestra BioMed Holdings Director David P Hochman Acquires 5,000 Shares - TradingView
Chmn Hochman Buys 5,000 ($20.4K) Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity - Stock Titan
Is this a good reentry point in Orchestra BioMed Holdings Inc.Day Trade & Free Verified High Yield Trade Plans - newser.com
Research Analysts Offer Predictions for OBIO FY2025 Earnings - Defense World
Barclays Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Overweight Recommendation - MSN
Will Orchestra BioMed Holdings Inc. stock recover after recent drop2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Can Orchestra BioMed Holdings Inc. stock withstand economic slowdownJuly 2025 Retail & Safe Swing Trade Setups - newser.com
Chmn Hochman Surrenders 6,566 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView
Views of Wall Street’s Leading Experts on Orchestra BioMed Holdings Inc - Setenews
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Orchestra BioMed Kicks Off Pivotal U.S. Trial of Non-Coated Sirolimus Balloon - MSN
Orchestra BioMed Secures FDA Breakthrough Designation - TipRanks
Orchestra BioMed Holdings, Inc. Provides Significant Business Updates - TradingView
[8-K] Orchestra BioMed Holdings, Inc. Reports Material Event | OBIO SEC FilingForm 8-K - Stock Titan
Orchestra BioMed Holdings Insiders May Regret Not Buying More, Market Cap Hits US$232m - simplywall.st
Can Orchestra BioMed Holdings Inc. stock reach $100 price target - newser.com
Barclays Maintains Orchestra BioMed Holdings (OBIO) Overweight Recommendation - Nasdaq
Barclays Lowers Price Target for OBIO While Maintaining Overweig - GuruFocus
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones - MSN
Orchestra BioMed to Deliver Major Business Update Amid Rapid Clinical Momentum - MSN
Orchestra BioMed Secures Funding And Upgrades Clinical Plans - Finimize
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - The Manila Times
Orchestra BioMed (NASDAQ: OBIO) to join Jefferies London and Piper; Dec. 3 fireside chat - Stock Titan
What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings - Yahoo Finance
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
0.53%
1.88%
大文字化:
|
ボリューム (24 時間):